

Puma Biotechnology Earnings Call Commercial Update




August 6, 2020

nerlynx[®]
(neratinib) tablets


Forward-Looking Safe Harbor Statement

This presentation contains forward-looking statements, including statements regarding the timing of expected launch and expected regulatory approvals for NERLYNX®. All statements other than historical facts are forward-looking statements and are based on the current expectations, forecasts and assumptions of Puma Biotechnology, Inc. (“Puma”). Forward-looking statements involve risks and uncertainties that could cause Puma’s actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements, including, but not limited to, any adverse impact on Puma’s business or the global economy and financial markets, generally, from the global COVID-19 pandemic, and other risk factors disclosed in the periodic and current reports filed by Puma with the Securities and Exchange Commission from time to time, including Puma’s Annual Report on Form 10-K for the year ended December 31, 2019, Puma’s Quarterly Report on Form 10-Q for the period ended June 30, 2020 and subsequent reports. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and you should not rely on these forward-looking statements as representing Puma’s views as of any date subsequent to the date of this presentation. Puma assumes no obligation to update these forward-looking statements, except as required by law.


PUMA's Pharmacy and Distributor Network



~\$48.8 Million Net NERLYNX Revenue in Q2'2020




~3,700 Commercial bottles were sold in Q2'20



Includes Commercial SP and SD

~31% of Patients in Q2'20 Started NERLYNX at a Reduced Dose



Reduced Dose defined as fewer than 6 pills per day

Rest of World Partnerships – Timelines

Region	Partner	Regulatory / Launch Milestones
Australia / SE Asia	 Specialised Therapeutics	<ul style="list-style-type: none"> March 2019 – Approved in Australia December 2019 -- Approved in Singapore Q2/Q3 2020 - Approved in Brunei, Malaysia, New Zealand
Israel	 MEDISON Delivering Innovative Healthcare	<ul style="list-style-type: none"> Q1 2020 - Launched
Canada	 Knight	<ul style="list-style-type: none"> July 2019 – Approved
Greater China	 CANbridge 北海康成	<ul style="list-style-type: none"> November 2019 – Approved in Hong Kong April 2020 – Approved in China August 2020 – Approved in Taiwan
Latin America	 PINT PHARMA	<ul style="list-style-type: none"> Q1 2020 – Argentina-Launched Q2 2020 – Approved in Chile 2H 2020 – Ecuador 2021 – Brazil, Colombia, Mexico, Peru
Europe Middle East North and West Africa South Africa Turkey	 Pierre Fabre	<p>Launch Timelines</p> <ul style="list-style-type: none"> Q4 2019 – Germany-Launched Q4 2019 – United Kingdom-Launched Q4 2019 – Austria-Launched Q1 2020 – Sweden Launched Q1 2020 – Approved in Switzerland 2020-2023 – Rest of Territory
South Korea	 BIXINK	<ul style="list-style-type: none"> End of 2020 – NDA Filing

Puma Biotechnology Earnings Call Commercial Update



August 6, 2020

nerlynx[®]
(neratinib) tablets